We are live on ! Find out more
SRGA

Surgalign Holdings, Inc. Common Stock

Delisted

SRGA was delisted on the 30th of June, 2023.

107 hedge funds and large institutions have $243M invested in Surgalign Holdings, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

23,600% more call options, than puts

Call options by funds: $237K | Put options by funds: $1K

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

51% more capital invested

Capital invested by funds: $161M → $243M (+$82.2M)

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

26% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 31

13% more funds holding

Funds holding: 95107 (+12)

Holders
107
Holders Change
+12
Holders Change %
+12.63%
% of All Funds
2.67%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
18
Increased
39
Reduced
31
Closed
6
Calls
$237K
Puts
$1K
Net Calls
+$236K
Net Calls Change
+$236K
Name Holding Trade Value Shares
Change
Change in
Stake
CI
76
Cigna Investments
Connecticut
$105K +$84.9K +597 New
Legal & General Group
77
Legal & General Group
United Kingdom
$100K
LCM
78
Landscape Capital Management
New Jersey
$87K -$44.7K -314 -39%
Squarepoint
79
Squarepoint
New York
$84K +$68.3K +480 New
Citadel Advisors
80
Citadel Advisors
Florida
$84K +$68.4K +481 New
MCM
81
Matarin Capital Management
New York
$80.8K +$65.4K +460 New
OAM
82
Oxford Asset Management
United Kingdom
$78K +$12.2K +86 +24%
VKH
83
Virtu KCG Holdings
New York
$77K +$62.2K +437 New
Principal Financial Group
84
Principal Financial Group
Iowa
$74K +$60K +422 New
CSS
85
Cubist Systematic Strategies
Connecticut
$68K +$55.5K +390 New
CS
86
Credit Suisse
Switzerland
$62K +$1.71K +12 +3%
PP
87
Paloma Partners
Connecticut
$61K +$49.8K +350 New
Barclays
88
Barclays
United Kingdom
$60K +$46.8K +329 +3,656%
KI
89
Koch Industries
Kansas
$60K +$48.5K +341 New
AIM
90
Acrospire Investment Management
Illinois
$40K -$7.11K -50 -18%
BNP Paribas Financial Markets
91
BNP Paribas Financial Markets
France
$38.5K +$28.9K +203 +1,269%
PCM
92
Prelude Capital Management
New York
$37K -$52.5K -369 -64%
Royal Bank of Canada
93
Royal Bank of Canada
Ontario, Canada
$30K -$32.4K -228 -57%
AIP
94
Ameritas Investment Partners
Nebraska
$26K
US Bancorp
95
US Bancorp
Minnesota
$26K +$4.69K +33 +29%
PAM
96
Paradigm Asset Management
New York
$25.2K +$20.3K +143 New
PS
97
Portfolio Solutions
Michigan
$10K +$1.42K +10 +21%
Creative Planning
98
Creative Planning
Kansas
$5K
JCM
99
Jacobi Capital Management
Pennsylvania
$5K
Group One Trading
100
Group One Trading
Illinois
$5K +$3.84K +27 New

SRGA Hedge Fund Activity: Q2 2017 in Review

107 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Surgalign Holdings, Inc. Common Stock (SRGA) for Q2 2017, worth a combined $243M — up 51% from $161M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SRGA positions and 6 closed out — a net gain of 12 holders — while 39 added to existing stakes and 31 trimmed.

The largest buyer was Rutabaga Capital Management, opening a new position worth an estimated $4M. The largest seller was Kennedy Capital Management, cutting an estimated $2.96M.

  • 107 institutional investors held Surgalign Holdings, Inc. Common Stock (SRGA) as of Q2 2017, up from 95 in Q1 2017.
  • Funds reported $243M of Surgalign Holdings, Inc. Common Stock stock for Q2 2017, up 51% quarter-over-quarter.
  • 18 funds opened new Surgalign Holdings, Inc. Common Stock positions in Q2 2017 and 6 closed out, a net change of +12 holders.
  • The largest Surgalign Holdings, Inc. Common Stock buyer in Q2 2017 was Rutabaga Capital Management, an estimated $4M added.
  • The largest Surgalign Holdings, Inc. Common Stock seller in Q2 2017 was Kennedy Capital Management, an estimated $2.96M sold.

Based on aggregated 13F filings for Q2 2017.